Aclarion adds University of Arizona to CLARITY trial network

Aclarion, Inc. (Nasdaq: ACON, ACONW) has added the University of Arizona College of Medicine – Phoenix as a clinical site in its CLARITY trial, bringing the total number of actively enrolling sites to ten, according to a company press release.

The CLARITY trial is a 300-patient, prospective, randomized, multi-center study evaluating Aclarion's Nociscan platform in patients undergoing surgical treatment for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm visual analog scale at 12 months compared to baseline. The company anticipates an initial internal data readout and public disclosure of early interim results in the fourth quarter of 2026.

Nicholas Theodore, MD, Chairman of Neurosurgery at the University of Arizona College of Medicine – Phoenix, will serve as Principal Investigator for the trial. "Chronic low back pain remains one of the most challenging problems in spine surgery, not because we lack the ability to treat it, but because identifying the precise disc responsible for a patient's pain has historically been imprecise," Theodore said in the statement.

The University of Arizona site joins existing CLARITY trial locations including Johns Hopkins University, Northwestern Medicine, Advocate Aurora Research Institute, Texas Back Institute, Keck Medicine at USC, UHealth — University of Miami Health System, Scripps Health, Lanman Spinal Neurosurgery, and Texas Spine Care Center.

Nociscan is a software-as-a-service platform that uses magnetic resonance spectroscopy and augmented intelligence algorithms to help physicians distinguish between painful and nonpainful discs in the lumbar spine.

You May Also Be Interested In

• JPMorgan Reiterates Overweight Rating on Legrand SA (LR:FP) (LGRDY) and Places on Positive Catalyst Watch
• PhillipCapital Downgrades Palo Alto Networks (PANW) to Neutral (3)
• Dr Lal PathLabs Ltd (DLPL:IN) PT Raised to INR2,150 at Nomura/Instinet